PMC:7417114 / 1883-2049
Annnotations
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T14","span":{"begin":47,"end":62},"obj":"Disease"},{"id":"T15","span":{"begin":53,"end":62},"obj":"Disease"},{"id":"T16","span":{"begin":112,"end":120},"obj":"Disease"}],"attributes":[{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"development of therapies targeting both direct viral infection and the inflammatory immune response elicited by SARS-CoV-2. While many patients with documented SARS-C"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"53","span":{"begin":112,"end":122},"obj":"Species"},{"id":"54","span":{"begin":135,"end":143},"obj":"Species"},{"id":"62","span":{"begin":47,"end":62},"obj":"Disease"}],"attributes":[{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"development of therapies targeting both direct viral infection and the inflammatory immune response elicited by SARS-CoV-2. While many patients with documented SARS-C"}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T7","span":{"begin":47,"end":62},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T8","span":{"begin":84,"end":99},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"development of therapies targeting both direct viral infection and the inflammatory immune response elicited by SARS-CoV-2. While many patients with documented SARS-C"}
LitCovid-PMC-OGER-BB
{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T40","span":{"begin":47,"end":52},"obj":"NCBITaxon:10239"},{"id":"T41","span":{"begin":84,"end":90},"obj":"UBERON:0002405;GO:0006955"},{"id":"T42","span":{"begin":91,"end":99},"obj":"GO:0006955"},{"id":"T43","span":{"begin":112,"end":122},"obj":"SP_7"},{"id":"T27895","span":{"begin":47,"end":52},"obj":"NCBITaxon:10239"},{"id":"T78024","span":{"begin":84,"end":90},"obj":"UBERON:0002405;GO:0006955"},{"id":"T16383","span":{"begin":91,"end":99},"obj":"GO:0006955"},{"id":"T70805","span":{"begin":112,"end":122},"obj":"SP_7"}],"text":"development of therapies targeting both direct viral infection and the inflammatory immune response elicited by SARS-CoV-2. While many patients with documented SARS-C"}